Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12525844 | 0.89 | L3MBTL1 (0.52) | L3MBTL1GAAPLA2G2AKMT2AALDH1A1 | |
| SCHEMBL16471651 | 0.84 | L3MBTL1 (0.49) | L3MBTL1GAAKAT6AMAOBPLA2G2A | |
| SCHEMBL22779381 | 0.84 | KAT6A (0.53) | L3MBTL1GAAKAT6AMAOBPLA2G2A | |
| SCHEMBL12526802 | 0.83 | L3MBTL1 (0.46) | L3MBTL1GAAMAOBPLA2G2AKMT2A | |
| SCHEMBL12523929 | 0.83 | CA5A (0.50) | L3MBTL1GAAMAOBPLA2G2AKMT2A | |
| SCHEMBL1205449 | 0.81 | L3MBTL1 (0.41) | L3MBTL1GAAMAOBPLA2G2AKMT2A | |
| SCHEMBL3022780 | 0.80 | KAT6A (0.49) | KAT6AMAOBKMT2AALDH1A1MEN1 | |
| SCHEMBL14227712 | 0.80 | MAPT (0.49) | L3MBTL1GAAMAOBPLA2G2AKMT2A | |
| SCHEMBL1205039 | 0.79 | F2R (0.46) | L3MBTL1GAAPLA2G2AKMT2AALDH1A1 | |
| SCHEMBL1765000 | 0.78 | LMNA (0.47) | L3MBTL1GAAMAOBKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | L3MBTL1 3732/4885GAA 3183/4885KAT6A 1490/4885 |
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | REN, AGTR1, AGTR2 | L3MBTL1 3732/4885GAA 3183/4885KAT6A 1490/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | L3MBTL1 4668/4885GAA 1408/4885KAT6A 1627/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | L3MBTL1 3732/4885GAA 3183/4885KAT6A 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.